Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response

Drug Metabolism and Drug Interactions

Volumn 29, Issue 2, 2014, Pages 67-79

  Jaramillo, Nancy Monroy ^b   Galindo, Ingrid Fricke ^c   Vázquez, Alberto Ortega ^c   Cook, Helgi Jung ^b   Lerena, Adrián ^d   López, Marisol López ^a  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^d UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Adverse drug reaction; Carbamazepine; Drug resistance; Genetic polymorphism; Human leukocyte antigen (HLA); Pharmacogenetics

Indexed keywords

BIOLOGICAL MARKER; CARBAMAZEPINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 2B7; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; ABC TRANSPORTER; ANTICONVULSIVE AGENT; CYTOCHROME P450; GENETIC MARKER;

ALLELE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; META ANALYSIS (TOPIC); PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; SYSTEMATIC REVIEW; ADVERSE DRUG REACTION; DRUG INTERACTION; DRUG RESISTANCE; GENETIC MARKER; GENETICS; IMMUNOLOGY;

ANTICONVULSANTS; ATP-BINDING CASSETTE TRANSPORTERS; CARBAMAZEPINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG HYPERSENSITIVITY; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC MARKERS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; PHARMACOGENETICS;

EID: 84904208935     PISSN: 07925077     EISSN: 21910162     Source Type: Journal    
DOI: 10.1515/dmdi-2013-0046     Document Type: Review

References (98)

1. Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure 1997;6:159-74. (Pubitemid 27290303)
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 2002;159(Suppl):S1-50.
3. Yukawa E. Investigation of phenobarbital-carbamazepinevalproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview. Drug Metabol Drug Interact 2000;16:86-98.
4. McMillin GA, Juenke JM, Tso G, Dasgupta A. Estimation of carbamazepine and carbamazepine-10,11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays. Am J Clin Pathol 2010;133:728-36.
5. Furst S, Uetrecht J. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol 1993;45:1267-75. (Pubitemid 23098324)
6. Ju C, Uetrecht JP. Detection of 2-Hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther 1999;288:51-6. (Pubitemid 29113472)
7. Staines AG, Coughtrie MW, Burchell B. N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther 2004;311:1131-7. (Pubitemid 39612720)
8. Kudriakova TB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 1992; 33:611-5.
9. Johannessen S, Johanessen C. Antiepileptic drug interactions -Principles and clinical implications. Current Neuropharmacol 2010;8:254-7.
10. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990;45:241-98. (Pubitemid 20008908)
11. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(Suppl):S2-12.
12. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Tran E, Berger R, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013;May 21. doi: 10.1038/clpt.2013.103 [Epub ahead of print].
13. Shastry CS, Shafeeque AA, Ashwathnarayana BJ. Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals. Indian J Pharmacol 2013;45:121-5.
14. Ferner RE, Butt TF. Adverse drug reactions. Medicine 2012;40:366-70.
15. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1000-15. (Pubitemid 46436124)
16. Ozaras N, Goksugur N, Eroglu S, Tabak O, Canbakan B, Ozaras R. Carbamazepine-induced hypogammaglobulinemia. Seizure 2012;21:229-31.
17. Jamal MA. Factors affecting the development of adverse drug reactions. Saudi Pharmaceutical J 2013;[article in press]. http://dx.doi.org/10.1016/j. jsps.2013.02.003.
18. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-10. (Pubitemid 14033827)
19. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84:417-23.
20. Aldaz A, Ferriols R, Aumente D, Calvo MV, Farre MR, García B, et al. Pharmacokinetic monitoring of antiepileptic drugs. Farm Hosp 2011;35:326-39.
21. Daly AK. Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv Pharmacol 2012;63:137-67.
22. Stern R. Exanthematous drug eruptions. N Engl J Med 2012;366:2492-501.
23. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;11:349-56.
24. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012;92:757-65.
25. Man C, Kwan P, Baum L, Yu E, Lau KM, Cheng A, et al. Association between HLA-B 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-8. (Pubitemid 46763406)
26. Ahijara M. Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol 2011;38:246-54.
27. Chung WH, Hung SI, Hong HS, Hsih M-S, Yang L-C, Ho H-C, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486. (Pubitemid 38480527)
28. U.S. Food and Drug Administration. FDA Safety Alerts for Human Medical Products. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150841.htm. Accessed December 2, 2013.
29. McCormack M, Alfirevic A, Bourgeois S, Farrel JJ, Kasperaviciut D, Carrington M. HLA-A 3101 and carbamazepineinduced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43.
30. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B 1502 allele in Thai population. Epilepsia 2008;49:2087-91.
31. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B 1511 is a risk factor for carbamazepine-induced Stevens Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010;51:2461-65.
32. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306.
33. Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011;97:190-7.
34. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, et al. Genome-wide association study identifies HLA-A 3101 allele as a genetic risk factor for carbamazepineinduced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011;20:1034-41.
35. Li LJ, Hu FY, Wu XT, An DM, Yan B, Zhoy D. Predictive markers for carbamazepine and lamotrigine-induced maculopapular exantherma in Han Chinese. Epilepsy Res 2013; pii: S0920-1211(13)00144-7. doi: 10.1016/j.eplepsyres.2013. 05.004. [Epub ahead of print].
36. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001;56:890-6. (Pubitemid 32290806)
37. Alfiveric A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 2006;16:287-96.
38. Thorn CF, Leckband SG, Kelsoe J, Leeder JS, Müller DJ, Klein TE, et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics 2011;21:906-10.
39. Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 2013;14:35-45.
40. Park PW, Seo YH, Ahn JY, Kim KA, Park JY. Effect of CYP3A5 3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009;34:569-74.
41. Seo T, Nakada N, Ueda N, Hagiwara T, Hashimoto N, Nakagawa K, et al. Effect of CYP3A5 3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. Clin Pharmacol Ther 2006;79:509-10.
42. Hung CC, Chang WL, Ho JL, Tai JJ, Hsieh TJ, Huang HC, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 2012;13:159-69.
43. Nakajima Y, Saito Y, Shiseki K, Fukushima-Uesaka H, Hasegawa R, Ozawa S, et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol 2005;61: 25-34. (Pubitemid 40558276)
44. Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, et al. UGT2B7-161C >T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 2010;32:177-84.
45. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8. (Pubitemid 36407173)
46. Sterjev Z, Trencevska GK, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska JT, et al. The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. Neuropsychiatr Dis Treat 2012;8:191-6.
47. Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 2010;19:93-101.
48. Kim WJ, Lee JH, Yi J, Cho YJ, Heo K, Lee SH, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 2010;20: 249-56.
49. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-Analysis. Epilepsia 2009;50:898-903.
50. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, et al. RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci 2005;6:61.
51. Soranzo N, Kelly L, Martinian L, Burley MW, Thom M, Sali A, et al. Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia 2007;48:674-83. (Pubitemid 46587613)
52. Leschziner GD, Jorgensen AL, Andrew T, Williamson PR, Marson AG, Coffey AJ, et al. The association between polymorphisms in RLIP76 and drug response in epilepsy. Pharmacogenomics 2007;8:1715-22.
53. Ufer M, von Stülpnagel C, Muhle H, Haenisch S, Remmler C, Majed A, et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics 2011;21:624-30.
54. Zhou BT, Zhou QH, Yin JY, Li GL, Qu J, Xu XJ, et al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther 2012;18:566-72.
55. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005;102:5507-12. (Pubitemid 40530288)
56. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepineresistant epilepsy. Br J Clin Pharmacol 2008;66:304-7.
57. Kumari R, Lakhan R, Kumar S, Garg RK, Misra UK, Kalita J, et al. SCN1AIVS5-91G > A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie 2013;95:1350-3.
58. Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 2008;18:989-98.
59. Kumari R, Lakhan R, Kalita J, Misra UK, Mittal B. Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population. Seizure 2010;19:237-41.
60. Kumari R, Lakhan R, Kalita J, Garg RK, Misra UK, Mittal B. Potential role of GABAA receptor subunit; GABRA6, GABRB2 and GABRR2 gene polymorphisms in epilepsy susceptibility and pharmacotherapy in North Indian population. Clin Chim Acta 2011;412:1244-8.
61. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 2007;115:232-42. (Pubitemid 46449584)
62. Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, et al. Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica 2009;39:140-7.
63. Maekawa K, Harakawa N, Yoshimura T, Kim SR, Fujimura Y, Aohara F, et al. CYP3A4 16 and CYP3A4 18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos 2010;38:2100-4.
64. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002;30:883-91. (Pubitemid 34815417)
65. Makmor-Bakry M, Sills GJ, Hitiris N, Butler E, Wilson EA, Brodie MJ. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin Neuropharmacol 2009;32:205-12.
66. Bauer JE, Gerber N, Lynn RK, Smith RG, Thompson RM. A new N-glucuronide metabolite of carbamazepine. Experientia 1976;32:1032-3.
67. Maggs JL, Pirmohamed M, Kitteringham NR, Park BK. Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography mass spectrometry. Drug Metab Dispos 1997;25:275-80. (Pubitemid 27120571)
68. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000 Nov;10:679.
69. Innocenti F, Liu W, Fackenthal D, Ramírez J, Chen P, Ye X, et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 2008;18:683-97.
70. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9. (Pubitemid 30075244)
71. Lazarowski A, Czornyj L. Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions. Drug Metabol Drug Interact 2011;26:21-6.
72. Beck H. Plasticity of antiepileptic drug targets. Epilepsia 2007;48(Suppl):S14-8.
73. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602. (Pubitemid 41059334)
74. Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS, Zulkifli SZ, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-Analysis. Seizure 2010;19:339-46.
75. Nurmohamed L, Garcia-Bournissen F, Buono RJ, Shannon MW, Finkelstein Y. Predisposition to epilepsy -does the ABCB1 gene play a role? Epilepsia 2010;51:1882-5.
76. Potschka H, Fedrowitz M, Löscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003;306:124-31. (Pubitemid 36734365)
77. Subenthiran S, Abdullah NR, Joseph JP, Muniandy PK, Mok BT, Kee CC, et al. Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital. PLoS One 2013;8:e64827.
78. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8. (Pubitemid 30183327)
79. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71:297-303. (Pubitemid 34311459)
80. Ozgon GO, Bebek N, Gul G, Cine N. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur Neurol 2008;59:67-70. (Pubitemid 350277263)
81. Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 2011;21:27-30.
82. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Häsler R, et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C ?T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 2009;19:353-62.
83. Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 2011;12:1525-33.
84. Depondt C. Epilepsy pharmacogenetics: science or fiction?. Med Sci 2013;29:189-93.
85. Dickens D, Yusof SR, Abbott NJ, Weksler B, Romero IA, Couraud PO, et al. A multi-system approach assessing the interaction of anticonvulsants with P-gp. PLoS One 2013;8:64854.
86. Krasowski MD. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals (Basel) 2010 Jun;3:1909-35.
87. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 2007;8:1151-8.
88. Haerian BS, Lim KS, Mohamed EH, Tan HJ, Tan CT, Raymond AA, et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure 2011;20:387-94.
89. Catterall WA. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron 2000;26:13-25.
90. Catterall WA, Kalume F, Oakley JC. NaV1.1 channels and epilepsy. J Physiol 2010;588:1849-59.
91. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics 2006;16:721-26. (Pubitemid 44454866)
92. Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, et al. Nova2 interacts with a cis-Acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet 2007;80:876-83. (Pubitemid 46668456)
93. Song W, Liu Z, Tan J, Nomura Y, Dong K. RNA editing generates tissue-specific sodium channels with distinct gating properties. J Biol Chem 2004;279:32554-61. (Pubitemid 39014711)
94. Zimprich F, Stogmann E, Bonelli S, Baumgartner C, Mueller JC, Meitinger T, et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 2008;49: 1108-9. (Pubitemid 351794005)
95. Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 2011;52:40-4.
96. Sills G, Mohanraj R, Butler E. A single-nucleotide polymorphism in the SCN2A gene is associated with uncontrolled epilepsy. Epilepsia 2004;45:(Suppl):S226.
97. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol 2009;68: 214-20.
98. Uebachs M, Opitz T, Royeck M, Dickhof G, Horstmann MT, Isom LL, et al. Efficacy loss of the anticonvulsant carbamazepine in mice lacking sodium channel beta subunits via paradoxical effects on persistent sodium currents. J Neurosci 2010;30:8489-501.